Projects
Confidential projects across pharmaceuticals and the life sciences — each teaser is available to view and download in full. From clinical-stage platforms and specialty manufacturers to royalty and profit-share structures.
Featured Teasers
Select a project to view the complete teaser and download a copy.
Confidential Project
GLP-1 Analog · Obesity & T2D
A novel long-acting GLP-1 analog engineered for potential once-monthly subcutaneous administration in obesity and type 2 diabetes, with preclinical efficacy benchmarked against semaglutide.
Read More →Confidential Project
DMA-free IV Busulfan · 505(b)(2)
Late-stage pharmaceutical company advancing Bivante, a DMA-free IV busulfan formulation for stem cell transplant conditioning, on a defined 505(b)(2) regulatory path.
Read More →Confidential Project
U.S. Royalty · First Generic Biologic
A U.S. royalty opportunity of up to 10% on net sales of the first generic version of THC, a complex biologic used in chronic autoimmune disorders.
Read More →Confidential Project
Specialty Pharma / CDMO · Sterile Expansion
US FDA, TGA and EU GMP approved specialty pharmaceutical company seeking US$14M to expand into higher-margin sterile manufacturing capabilities.
Read More →Confidential Project
Nutraceuticals · Marine Collagen Platform
A patented, first-of-its-kind jellyfish collagen platform targeting brain, gut, immunity and healthy-aging applications, supported by emerging human clinical data.
Read More →Confidential Project
Ultrasound MedTech · Theranostics
A proprietary microbubble and nanobubble platform that extends ultrasound from imaging to therapy, with a Phase II contrast agent and therapeutic programs.
Read More →Confidential Project
Pharma Services · Regulatory Compliance
A global GxP compliance, regulatory affairs and technology services platform for generic pharmaceutical, API and biosimilar companies — 100% sale with management continuity.
Read More →Confidential Project
Injectable Biologic · Frozen Shoulder
A non-surgical, office-based injectable approach to adhesive capsulitis and capsular fibrosis, advancing toward independent GCP-aligned clinical validation.
Read More →Confidential Project
Respiratory Generics · Profit Share
A U.S. profit-share interest tied to the anticipated first generic entry across a differentiated, device-enabled respiratory franchise.
Read More →Confidential Project
Specialty Pharma · Transdermal 505(b)(2)
A privately held specialty pharmaceutical company advancing transdermal 505(b)(2) drug programs across CNS, cardiovascular, metabolic, oncology and autoimmune markets.
Read More →Confidential Project
Ophthalmology · Anti-VEGF (VVCA-101)
A clinical-stage platform company developing patented anti-VEGF therapies for high-unmet-need ophthalmology and dermatology indications.
Read More →Additional Projects
Additional opportunities currently in process — full details available upon inquiry.
Confidential Project
U.S. CDMO · Solid Dose & Small Molecule
An established U.S.-based CDMO specializing in solid dose and small molecule drug products, delivering end-to-end development, manufacturing and packaging under FDA-approved cGMP facilities, with infrastructure to expand into additional dosage forms.
Read More →Confidential Project
US$40–60M · 30%–49% Equity Stake
Partner with a proven, export-oriented specialty pharmaceutical company serving 200+ global pharma clients and positioned for high growth in complex generics and innovative delivery systems.
Read More →Confidential Project
OTC & CMO Services · Est. 1997
A pharmaceutical company established in 1997 specializing in OTC products, effervescent tablets, food supplements, medical devices, chewables and ODTs, offering contract manufacturing and private label services while scaling CMO capacity following a new biotech facility investment.
Read More →Confidential Project
U.S. Branded Respiratory · Global Footprint
A US-established pharmaceutical company focused on high-value branded respiratory products, with operations in over 25 countries. This opportunity is for equity in the US company, enabling direct participation in the fast-growing US respiratory market.
Read More →Confidential Project
High-Capacity CDMO · €55M Net Revenue
A CDMO established in 2015 with ~400 employees, offering high-capacity solid oral dosage production, packaging and full drug substance and product services via a major biotech facility investment, with worldwide distribution and €55M net revenue in 2022.
Read More →Confidential Project
Maternal Health · Virtual Pharma
A virtual pharma company (est. 2006) owned by three physician-inventors, specializing in a branded portfolio of prenatal, postnatal and gynecological food supplements and medical devices, seeking a strategic investor or partner to unlock international expansion.
Read More →Confidential Project
Drug Discovery CRO · Immuno-Oncology
A drug discovery CRO established in 2005 with 54 employees, specializing in immuno-oncology, immune-modulation and lung diseases through integrated discovery, in vivo pharmacology, medicinal chemistry, bioanalytics and formulation services for major clients.
Read More →Confidential Project
Compact CDMO · 70%–100% Stake Available
A compact CDMO and own-brand distributor with 15 employees, two manufacturing units for pharmaceuticals and food supplements, worldwide partner distribution and $4.5M net revenue, with owners open to a 70% stake or a full 100% exit.
Read More →Confidential Project
Consumer Health · Eastern Europe
Immediate entry into an expanding consumer health, food supplements and branded generics market, featuring high-margin branded assets, a marketing-driven growth engine, loyal distribution and a turnkey sales & regulatory platform for Eastern European expansion.
Read More →Confidential Project
Manufacturer · MAH · 19 Countries
A pharmaceutical company established in 2016 serving as manufacturer, distributor and MAH with 5 branded products and CDMO contracts across 19 countries, certified across multiple dosage forms with a new injectables line under investment, seeking acquisition or strategic investment.
Read More →Confidential Project
$70M Revenue · 28% EBITDA · 100% Acquisition
A debt-free, privately owned pharmaceutical company established in 1987, with $70M revenue, 28% EBITDA and 58 branded generic RX products focused on oncology, hematology, rheumatology, orphan drugs and rare diseases, distributed in 40 countries.
Read More →Confidential Inquiries
Reach out to discuss any opportunity in detail, under appropriate confidentiality.
